Company news
Tristel Plc (LSE:TSTL) news
Tristel Plc news releases on 6ix. Latest, Sep 30, 2026: Notice of Results
Press releases & updates
Notice of Results
September 30, 2026
3T Pro commercial launch
July 27, 2026
Positive Trading Update
July 22, 2026
APIC26 Annual Conference attendance
July 7, 2026
Exercise of Share Options & Total Voting Rights
June 10, 2026
Conference attendance at ShareSoc Leeds
March 18, 2026
PCA Dealing
March 3, 2026
Half-year Financial Report
March 2, 2026
Exercise of Share Options and Total Voting Rights
February 6, 2026
Notice of Results
February 6, 2026
Positive H1 Trading Update & Directorate Change
January 22, 2026
Director/PDMR Shareholding
December 12, 2025
Result of AGM
December 11, 2025
AGM Statement
December 11, 2025
Director Option Grant
November 24, 2025
Updated US guidelines for high level disinfection
November 24, 2025
AIUM Expands Guidelines to Include Chlorine Dioxide for High-Level Disinfection of Ultrasound Probes
November 19, 2025
Notice of AGM & Posting of Annual Report &Accounts
November 18, 2025
Holding(s) in Company
November 12, 2025
Final Results
October 13, 2025
VISICLEAN Product Launch
September 25, 2025
Notice of Preliminary Results
September 16, 2025
Confirmation of CFO Appointment
September 1, 2025
Capital Markets Day video update
August 6, 2025
Trading update
July 29, 2025
Confirmation of Investor presentations
July 24, 2025
Appointment of Chief Financial Officer
July 17, 2025
APIC25 Annual Conference attendance
June 26, 2025
Investor Presentations & Notice of Trading Update
June 2, 2025
Conference attendance at Mello2025 Investor event
May 28, 2025
CFO succession planning
May 15, 2025
FDA clearance for Tristel OPH
May 12, 2025
Additional info. submitted to FDA for Tristel OPH
April 10, 2025
Publication of Poster by Mayo Clinic & US update
April 9, 2025
Unaudited Interim Results
February 24, 2025
Tristel : Interim Result 2025
February 20, 2025
Confirmation of Interim Results
January 13, 2025
AGM Statement and Notice of Interim Results
December 16, 2024
FDA 510(k) submission for Tristel OPH
September 12, 2024
Confirmation of CEO Transition, Directorate Change
September 2, 2024
Trading Update
July 22, 2024
Appointment of CEO
June 10, 2024
Tristel™ ULT case study
May 8, 2024
Half-year Report
February 26, 2024
UK and EU regulatory approval update
February 26, 2024
Notice of Interim Results
February 1, 2024
Canadian regulatory approval for Tristel ULT
January 23, 2024
Audited Preliminary Results
October 16, 2023
Additional Investor Presentation
October 12, 2023
Health Canada regulatory approval submission
September 4, 2023